Tesofensine is a small molecule that inhibits neurotransmitter reuptake. It is not a peptide or a GLP-1 medicine. Evidence for tesofensine alone must be distinguished from the combination Tesomet.
What the research shows
A 2008 phase 2 obesity trial reported greater weight loss than placebo, alongside adverse events and increased heart rate in a treatment group. The 2022 Tesomet study used a combination with metoprolol in hypothalamic obesity, a different formulation and population. [1] [2]
Distinguishing substances and products
Tesomet findings do not establish identical outcomes or limitations for tesofensine alone. Historical trial weight changes should not be presented as promises to an individual customer.
Reading a specific brand’s label
Start with the exact substance and product name, then match the label to the manufacturer’s documents. This article does not establish Thai registration or current availability for an unspecified product.
Frequently asked questions
Is tesofensine a peptide?
No. It is a small molecule with a mechanism distinct from GLP-1 medicines.
How does Tesomet differ?
The cited Tesomet trial studied tesofensine combined with metoprolol, not tesofensine alone.
What information helps identify a specific product?
The brand, product name, full label and matching manufacturer documents. Evidence about the substance alone does not establish a product’s identity, registration or quality.
Related information
For general questions about names or label details, contact LINE: @musclestationth
Sources and review date
Sources checked: 11 September 2026. This page explains selected primary sources; it is not a systematic review of every study.